Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2

Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)